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Abstract: Hidradenitis suppurativa (HS) is a chronic, recurrent and debilitating inflammatory skin
disease of the hair follicle that usually presents as painful, deep-seated inflamed lesions in the apocrine
gland-bearing areas of the body. HS patients suffer from uncomfortable signs and symptoms, such as
pain, pruritus, malodour and suppuration, which may impair patients’ quality of life (QoL). Although
HS patients frequently experience these signs and symptoms, they are only occasionally assessed
by clinicians and, unexpectedly, the scientific evidence available is limited and heterogeneous. The
aim of this study is to summarize the evidence regarding the impact of HS signs and symptoms
on QoL to serve as a basis for future research and help clinicians to consider them in the daily
care of HS patients. A systematic review and meta-analysis were conducted following PRISMA
Guidelines. The following search algorithm was used: (hidradenitis or “acne inversa”) and (pain
or itch or odour or malodour or suppuration or oozing or drainage) and (“quality of life”). The
literature search identified 836 references, 17 of them met the eligible criteria and were included
for analysis, representing 4929 HS patients. Mean age of the participants was 36.28 years and there
was a predominance of female sex among study participants. The BMI of the population was in
the range of over-weight and about two out five patients were active smokers. Studies included
patients with mild to moderate HS, with a mean disease duration of 13.69 years. The HS signs and
symptoms assessed were pain, pruritus, malodour and suppuration. Overall, the higher intensity
of a sign or symptom correlated with poorer general QoL or specific QoL dimensions including
sexual distress, anxiety, depression and sleep. The most frequently employed tool to assess QoL was
the Dermatology Life Quality Index (DLQI). DLQI was used in 52.9% of the studies (9/17) with a
mean value of 10.70 (2.16 SD). The scores employed to assess signs and symptoms severity were
subjective and varied between studies, being the numerical rating scale (NRS) for each of the most
used symptoms. The mean NRS value for pain was 3.99 and the mean NRS for pruritus was 4.99. In
conclusion, we have summarized, categorized and analyzed the scientific evidence regarding signs
and symptoms in HS patients and their impairment in QoL. Their assessment should be thorough
and included during routine evaluation of HS patients to motivate therapeutic modifications and
increase patients’ health.
Keywords: acne inversa; dermatology; hidradenitis suppurativa; quality of life; pain; pruritus
1. Introduction
Hidradenitis suppurativa (HS) is a chronic, recurrent and debilitating inflammatory
skin disease of the hair follicle that usually presents after puberty with painful, deep-seated
inflamed lesions in the apocrine gland-bearing areas of the body, most commonly the
axillae, inguinal and anogenital regions [1,2]. It has an estimated prevalence rate in the
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general population of 1% [3] and is associated with several comorbidities, such as metabolic
syndrome, cardiovascular risk, diabetes or inflammatory bowel disease [4].
HS is one of the dermatological diseases with the greatest impact on patients’ quality
of life (QoL) [5]. Its impairment is similar to other conditions, such as cardiovascular
disease, cancer, diabetes mellitus and chronic obstructive pulmonary disease [6]. In fact,
the mean Dermatology Life Quality Index scores for HS (8.3–12.7) are typical for severe
dermatoses [7]. The disease severity, the number of flares and the lesion location are
major factors impairing QoL [7,8]. HS not only impairs the physical health but also mental
and psychosocial health. Poor self-esteem and body image [9,10] and increased risk of
anxiety and depression [11,12] are also factors associated with HS that worsen patients’ life.
Moreover, HS has a negative effect on sexual function [13].
The tool used most frequently to assess patients’ QoL is the DLQI. Recently, disease
specific instruments to assess quality of life in HS have been developed [14], such as
the HSQoL-24 validated in the Spanish population [15]. Other questionnaires also em-
ployed to evaluate psychosocial and physical functioning in HS are Skindex, the EuroQol
5 Dimensions questionnaire (EQ-5D) and the Short Form 36 questionnaire (SF-36). The
Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI) and
Major Depression Inventory (MDI) have been used to assess the impact on psychological
QoL [7]. The influence of sexual function on patients’ life has also been evaluated using
different questionnaires, such as the six-item Female Sexual Function Index (FSFI-6) and
the Five-Item International Index of Erectile Function (IIEF-5) [13].
The great impact on QoL might be in part due to its uncomfortable signs and symp-
toms. HS lesions produce pain, pruritus, malodour and suppuration, which make life
difficult for patients [16,17]. Pain seems the most common and bothersome symptom of HS
and it is usually linked to the inflammatory nodules or abscesses, reported by more than
95% of patients [7]. The pain reported in HS patients is higher than other skin diseases [18].
The pain is not specific to any location on the body and it is mainly described as shooting,
itchy and blinding [19]. Regarding other HS symptoms, pruritus is the other one most
overlooked in the literature, although HS is not usually considered a pruritic disease [20].
The most common tools used to evaluate the severity of HS symptoms are the visual
analogue scale (VAS) and the numerical rating scale (NRS) [7].
Pain, pruritus, malodour and suppuration are signs and symptoms frequently expe-
rienced by patients, but they are only occasionally assessed by clinicians [21]. Signs and
symptoms might be the main burden of patients with HS, producing a great impairment in
quality of life. Unexpectedly, the scientific evidence available is limited and heterogeneous.
The aim of this study is to summarize the evidence regarding the impact of HS signs and
symptoms on QoL to serve as a basis for future research and help clinicians to consider
them in the daily care of HS patients.
2. Materials and Methods
A systematic review and meta-analysis were conducted. A literature search was
performed using Medline, Scopus and Embase databases from conception to 4 May 2021,
following PRISMA Guidelines (Supplementary Material). The following search algorithm
was used: (hidradenitis or “acne inversa”) and (pain or itch or odour or malodour or
suppuration or oozing or drainage) and (“quality of life”). Symptoms included in the
literature search were selected by a dermatologist expert in HS (AML) following the most
recent evidence in HS clinical presentation [1].
The search was limited to: (i) human data, (ii) articles correlating HS symptoms
with quality-of-life impairment in HS patients, (iii) articles written in English. All types
of epidemiological studies (clinical trials, cohort studies, case-control studies and cross-
sectional studies) were included and analyzed. Reviews, guidelines, protocols, case series,
case reports and conference abstracts were excluded.
Two researchers (TMV and AML) independently reviewed the titles and abstracts
of the articles obtained in the first search to assess relevant studies. The full texts of all
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articles meeting the inclusion criteria were reviewed, and their bibliographic references
were checked for additional sources. The articles considered relevant by both researchers
were included in the analysis. Disagreements about inclusion or exclusion of articles were
subjected to discussion until a consensus was reached. If not reached, resolution was
achieved by discussion with a third researcher (SAS).
The variables assessed were study design, author, country, level of scientific evidence
according to the Centre for Evidence-Based Medicine, number of participants, age, sex, BMI
(kg/m2), smoking habit, disease duration, disease severity (Hurley stage), HS symptoms
and aspects of QoL evaluated, QoL and symptoms assessment tools and scores, correlation
between symptoms and QoL.
The mean DLQI and NRS for symptoms was calculated by a random effect meta-
analysis weighted by the study sample size. To estimate absolute mean effect of DLQI
and NRS for each symptom, the mean, standard deviation and sample size were extracted
from the studies. Research with unclear or incomplete reporting was excluded from the
meta-analysis. To generate valid estimates, studies were weighed according to their sample
size. Forest plots were constructed to assess the distribution of the data and summarize
the effect size and their 95% CIs. Quantifying of Heterogeneity was evaluated using
Cochrane Q statistic, an intermediary statistic employed to obtain a more useful measure
of heterogeneity, the I2. Assuming a high heterogenicity between studies, we used a
random effects model to calculate the outcome. Microsoft Excel version 2016, Redmond,
Washington, The USA, was used to run this data [22].
The quality of the design was critically appraised using the National Institutes of
Health quality assessment tool to evaluate risk of bias (Table S1) [23]. This tool is based on
the key concepts for evaluating the internal validity of a study and is divided into a set of
14 set questions. Studies are classified depending on the rate: good quality (>9 criteria met),
fair quality (5–9 criteria met) and poor quality (<5 criteria met).
3. Results
The literature search identified 836 references, 523 after removing duplicated papers.
After reviewing the title and abstract, 92 records underwent full-text review. A total of
75 records were excluded because they did not investigate the impact of HS symptoms on
QoL. Other reasons for exclusion along with the flow chart are shown in Figure 1. Finally,
17 studies, representing 4929 patients with HS, met the eligible criteria and were included
and fully reviewed [24–40].
The main characteristics of the studies included are summarized in Table 1. All studies
had a cross-sectional design and were classified as scientific level of evidence 4. Samples
were recruited from outpatient clinics or through focused electronic, postal or telephone
surveys. Study participants were predominantly female. Mean age of the participants was
36.28 years. The BMI of the population was in the range of overweight, about two out five
patients were active smokers. Studies included patients with mild to moderate HS, with a
mean disease duration of 13.69 years. The body regions more frequently affected by HS
were axilla and groins.
The HS signs and symptoms assessed were pain, pruritus, malodour and suppuration.
Overall, the higher intensity of a sign or symptom correlated with poorer general QoL
or specific QoL dimensions including sexual distress, anxiety, depression and sleep. The
most frequently employed tool to assess QoL was the DLQI. DLQI was used in 52.9% of
the studies (9/17) with a mean value of 10.70 (2.16 SD) after conducting a random effect
meta-analysis weighted by the study sample size (Figure 2).




Figure 1. Flow chart of the studies included. 
 
Figure 2. Meta-analysis of the mean Dermatology Life Quality Index reported in the studies. 
Figure 1. Flow chart of the studies included.
3.1. Pain
Thirteen studies evaluated the impact of pain in the QoL of HS patients, including
4216 participants with a mean age of 35.62 years (Table 2) [24–36].
The incidence of pain was reported in two studies, ranging from 65.24% [33] to
77.5% [32]. NRS was the scale most used to assess pain (53.85%, 7/13) [24,25,30–34].
The mean NRS value was 3.99 (SD 0.95) after conducting a random effect meta-analysis
weighted by the study sample size (Figure 3). VAS was the second most employed tool for
pain but was scored in different ways [26,27,29,32,35]. PainDETECT [27], boil-associated
pain score [28] and self-reported number of painful lesions [36] were other ways of pain
severity assessment.
The most frequently employed tool to assess QoL was the DLQI [26–29,31–33,35].
Skindex-29 [26], patient global assessment (PtGA) of QoL [30] and Skindex-17 [35] were
also employed to assess overall QoL in HS patients. The Hospital Anxiety and Depression
Scale (HADs)-Anxiety was used to assess anxiety [26] and HADS-depression [26], Beck’s
Depression Inventory [27] and Major Depression Inventory (MID) [34] were employed
to evaluate depression. Sexual distress was assessed by NRS for HS impact on sex life,
six-item Female Sexual Function Index (FSFI-6) and five-item International Index of Erectile
Function (IIEF-5) [24,25]. The impairment of sleep was assessed by using the Athens
Insomnia Scale (AIS) and the Pittsburgh Sleep Quality Index (PSQI) [29].
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Table 1. Main characteristics of the studies regarding HS symptoms impact on QoL.

















Alavi et al. Canada
2017 [37]
Cross-
sectional 4 51 32.50 ± 10.76 2.47:1 NS NS 11.10 ± 8.57
13.7% (7)/45.1%






















Frings et al. Germany.
2019 [26]
Cross-
sectional 4 110 38 ± 12 1.24:1 30.5 ± 6.9 37% (41) NS 7% (8)/30% (33)/63% (69) Pain
Overall QoL, anxiety
and depression
Huilaja et al. Finland.
2020 [27]
Cross-






sectional 4 339 39.4 ± 13.5 1.80:1 29 ± 7.6 75.2% (255) 13.8 ± 11.5
28.3% (96)/
57.5% (195)/14.2% (48) Pain Overall QoL
Kaaz et al. Poland. 2018
[29]
Cross-
sectional 4 108 36.3 ± 12.1 0.89:1 28.8 ± 5.4 18% (60) 9.1 ± 8.3
46.3% (50)/45.4% (49)/
8.3% (9) Pain and pruritus Sleep and insomnia
Kirby et al. Denmark
and USA. 2021 [30]
Cross-





sectional 4 1795 40.0 ± 11.8 1.79:1 28.1 ± 6.2 55.6% (998) NS NS Pain Overall QoL
Machado et al. Canada.
2021 [38]
Cross-
sectional 4 30 40.87 ± 2.55 2.33:1 NS NS NS NS
Malodour and
drainage Overall QoL
Matusiak et al. Poland
2018. [32]
Cross-
sectional 4 103 35.6 ± 13.2 0.94:1 29.4 ± 5.7 54.4% (56) 8.9 ± 7.5
40.8% (42)/45.6%





sectional 4 233 40.14 ± 13.46 1.14:1 30.68 ± 7.05 NS 13.99 ± 10.59
30.04% (70); 41.63% (97);




sectional 4 211 43.0 ± 11.8 NS NS NS 16.8 ± 11.6
30.1% (64)/56.4%
(119)/13.5% (28) Pain and pruritus
Overall QoL and
depression
Riis et al. Denmark.
2016 [39]
Cross-





Sampogna et al. Italy
2019 [35]
Cross-
sectional 4 69 34.5 ± 12.5 1.16:1 NS NS NS
27.5% (19)/43.5%
(30)/29.0% (20) Pain Overaal QoL
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Table 1. Cont.

















von der Werth et al.
Denmark. 2001 [36]
Cross-









BMI, body mass index; CEBM, level of scientific evidence according to the Centre for Evidence-Based Medicine (24); DLQI, Dermatology Life Quality Index; HADS, Hospital Anxiety and Depression Scale; HS,
hidradenitis suppurativa; HSS, Hidradenitis Suppurativa Score; IHS4, International Hidradenitis Suppurativa Severity Index; NRS, Numeric Rating Scale; NS, not specified; QoL, quality of life, VAS, visual
analogue scale. Continuous data is expressed as media ± SD or median (interquartile range) and categorical data are presented as n or n/N (%). * The article contains this information in the Supplementary
Material but it is not accessible (broken link).
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Figure 2. Meta-analysis of the mean Dermatology Life Quality Index reported in the studies.
Pain was related to the overall impact on QoL, assessed by DLQI independently of the
tool used for assessing QoL and pain severity [26–28,30,32,33,35,36]. High NRS for pain
was associated with high DLQI [31–34] (r = 0.581, p < 0.001 [31]; r = 0.48, p < 0.001 [32];
β = 0.91 ± 0.12, R2 = 0.36, p < 0.001 [33]; r = 0.60, p < 0.05 [34]) and PtGA of QoL (r = 0.66,
0.6–0.71 95% CI) [30]. High VAS for pain values were also linked to higher DLQI (r = 0.457,
p < 0.001 [26]; r = 0.48, p < 0.001 [32]), Skindex-29 [26] and Skindex-17 [35]. Matusiak et al.
showed that the presence of pain was a more important factor for worsening QoL (p = 0.002)
than disease severity (p = 0.04). They also observed that pain severity was related to
increased sweating, heat and physical activity [32].
Two studies showed that HS pain worsened psychological QoL [27,34]. Nevertheless,
Frings et al. showed that pain impairs patients’ anxiety (r = 0.304, p = 0.009) but not
depression (r = 0.193, p = 0.105) [26]. Kaaz et al. also found that HS pain was related to
poor sleep quality [29]. Moreover, it was observed that NRS for pain was related to impact
on sex life (β = 0.15, p = 0.049) [25] and was a risk factor for sexual dysfunction in females
(β = 0.1, p < 0.05) [24].
3.2. Pruritus
Eight studies evaluated the impact of pruritus on HS patients’ QoL, including 2059
participants with a mean age of 38.88 years (Table 3) [24,25,29,32–34,39,40].
The incidence of pruritus was reported in three studies (41.7% [32] vs. 57.3% [40]
vs. 61.8% [33]). The NRS for pruritus was the scale most used to assess pruritus
severity [24,25,32–34,39,40]. The mean NRS was 4.99 (0.96 SD), after conducting a random
effect meta-analysis weighted by the study sample size, Figure 4. VAS for pruritus [29],
4-item itch questionnaire [32] and 5-D itch scale [40].
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Pain and QoLAssessment Tool Score Assessment Tool Score
Cuenca-Barrales et al.
Spain. 2019 [25] NRS 6.54 ± 2.95 NRS for HS impact on sex life
7.24 ± 2.77 in
women
6.39 ± 3.44 in men





Women: 6.52 ± 2.98 Prevalence of sexual
dysfunction
FSFI-6 ≤ 19 51% (156) β = 0.1, p < 0.05 **
Men: 6.64 ± 2.81 IIEF-5 ≤ 21 60% (48) β = NS, p = 0.97 **
Frings et al. Germany.
2019 [26] VAS NS
DLQI 12 ± 7 r = 0.457, p < 0.001
HADS-Depression 6 ± 4 r = 0.193, p = 0.105
HADS-Anxiety 7 ± 4 r = 0.304, p = 0.009
Skindex-29 symptom score
NS
r = 0.547, p < 0.001
Skindex-29 function score r = 0.459, p < 0.001
Skindex-29 emotion score r = 0.399, p < 0.001
Huilaja et al. Finland.
2020 [27]
VAS:
-No pain (0–4 mm)/







3.03 (0–9) vs. 8.76
(0–23) vs. 13.69
(4–29)
p < 0.001 ¶
Beck’s Depression Inventory
6.68 (0–4.0) vs. 9.26
(0–30) vs. 13.06
(1–32)









4.53 (0–16) vs. 8.84
(1–23) vs. 10.55
(0–29)
p < 0.001 ¶
Beck’s Depression Inventory
6.84 (0–20) vs. 7.68
(0–19) vs. 12.86
(0–32)








15 ± 7.4 DLQI 11.9 ± 7.6
Mean difference:
6.3 ± 1.85, p < 0.001 Ü
Kaaz et al. Poland.
2018 [29] VAS 4.9 ± 2.9
DLQI 13.0 ± 8.0 NS
AIS 5.4 ± 4.3 p < 0.05 ˆ
PSQI 6.5 ± 3.6 p < 0.05 ˆ
Kirby et al. Denmark
and USA. 2021 [30] NRS 3.29 ± 2.83
DLQI 12.97 ± 8.33 NS




NRS NS DLQI 13.2 ± 8.1 r = 0.581; p < 0.001 ˆ
Matusiak et al. Poland.
2018 [32]




VAS 4.6 ± 2.5 r = 0.48, p < 0.001 ˆˆ




NRS 4.64 ± 3.43 DLQI 10.93 ± 7.3 β = 0.91 ± 0.12,R2 = 0.36, p < 0.001 *
Onderdijk et al.
Netherlands. 2013 [34] NRS 3.6 ±3.2
DLQI 8.4 ± 7.5 r = 0.60, p < 0.05 Ü
MDI 4.3 ± 5.6 r = 0.36, p < 0.05 Ü









Skindex-17 Symptoms 53.6 vs. 72.0 vs.72.6, p = 0.068
¶
Skindex-17 psychosocial 39.4 vs. 54.6 vs. 61.7 p = 0.088 ¶





Pain and QoLAssessment Tool Score Assessment Tool Score
von der Werthet al.
Denmark. 2001 [36]
Self-reported number
of painful lesions 2 DLQI 8.9 ± 8.3 r = 0.384, p < 0.01 Ü
AIS, Athens Insomnia Scale; DLQI, Dermatology Life Quality Index; FSFI-6, six-item Female Sexual Function Index; HADS, Hospital Anxiety
and Depression Scale; HS, hidradenitis suppurativa; IIEF-5, five-item International Index of Erectile Function; MDI, Major Depression
Inventory; NRS, Numeric Rating Scale; NS, not specified; PSQI, Pittsburgh Sleep Quality Index; PtGA, patient global assessment; QoL,
quality of life. * Simple linear regression analysis; ** Multivariate linear regression analysis; Analysis of variance; # Student’s t-test for
independent samples; ¶ Multivariate analysis of variance; Ü Spearman correlation; ˆ Pearson correlation; ˆˆ Pearson’s correlation coefficient
or Spearman’s correlation analysis with reference to the distribution of evaluated variables.
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Figure 3. Meta-analysis of the mean Numerical Rating Scale for pain reported in the studies.
Matusiak et al. observed that the presence of pruritus did not have an impact on
QoL [32], while Molina-Leyva et al. observed that the presence of NRS for pruritus > 3 was
related with higher rates in DLQI score (β = 0.42 ± 0.11, R2 = 0.20, p < 0.001) [33]. Moreover,
higher rates in VAS and NRS for pruritus were positively correlated with DLQI [32,34].
The impact of pruritus in overall QoL was also reflected by Riis et al. showing that higher
NRS for pruritus were related to lower values in the EQ-5D (β = −0.017, p < 0.05) [39].
It was found that HS pruritus impaired sleep quality [29,40] and it was linked to
poor mental health assessed by MDI [34]. Nevertheless, it was observed that NRS for
pruritus did not have an impact on sex life (β = 0.03, p = 0.615) [25], neither in men nor in
women [24].
Factors associated with increased risk of pruritus were Hurley III, higher number of
regions affected, the female sex, being an active smoker, the intensity of suppuration and
pain, having Crohn’s disease and not using statins [32,33,40].
3.3. Malodour
Six studies evaluated the impact of pain in the QoL of HS patients, including 1507
participants with a mean age of 38.59 years [24,25,33,37–39], Table 4.
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The incidence of malodour was reported in two studies, rating from 88.24% [37] to
40.8% [33]. NRS was the most common scale used to assess malodour severity [24,25,33,37,39],
ranging from 3.28 ± 3.58 [33] to 5.6 ± 3.38 [25]. HODS-odour was also used [38].






with PruritusAssessment Tool Score Assessment Tool Score
Cuenca-Barrales
et al. Spain. 2019
[25]
NRS 6.43 ± 2.96 NRS for HS impact on sexlife
7.24 ± 2.77 in
women and
6.39 ± 3.44 in men







6.48 ± 3.03 Prevalence
of sexual
dysfunction
FSFI-6 ≤ 19 51% (156) β = NS, p = 0.36 ** NS
Men:
6.24 ± 2.67 IIEF-5 ≤ 21 60% (48) β = NS, p = 0.28 ** NS
Kaaz et al.
Poland. 2018 [29] VAS 4.1 ± 2.9
DLQI 13.0 ± 8.0 NS
NSAIS 5.4 ± 4.3 p < 0.05 ˆ





DLQI 13.3 ± 7.8
p = 0.79 ¶
Hurley III, active
smokers ¶
VAS 3.9 ± 2.2 r = 0.45, p = 0.004 ˆˆ
NRS 4.3 ±2.1 r = 0.48, p = 0.002 ˆˆ
4-item Itch













β = 0.42 ± 0.11,
R2 = 0.20, p < 0.001 *
Number of regions
affected
(β = 0.51, p = 0.01),
female sex
(β = 0.46, p = 0.02),
intensity of
suppuration (β = 0.42,
p < 0.001), Crohn’s
disease (β = 1.24,
p = 0.01), not statin use




NRS 3.3 ± 3.1
DLQI 8.4 ± 7.5 r = 0.53, p < 0.05 Ü
NS
















Hurley stage III (OR
7.73; p = 0.003) and
higher levels of pain,
(OR = 1.34 for each
additional point on the
NRS, p = 0.001) #
NRS 3.7 ± 3.3
5-D itch scale 13.7 ± 3.6
ADL, activities of daily living; DLQI, Dermatology Life Quality Index; EQ-5D, EuroQoL-5D; FSFI-6, six-item Female Sexual Function
Index; HS, hidradenitis suppurativa; IIEF-5, Five-Item International Index of Erectile Function; MDI, Major Depression Inventory; NRS,
Numeric Rating Scale; NS, not specified; QoL, quality of life. * Simple linear regression analysis; **## Multivariate linear regression analysis;
# Multivariate logistic regression analysis; ¶ Multivariate analysis of variance; ÜSpearman correlation; ˆ Pearson correlation; ˆˆ Pearson’s
correlation coefficient or Spearman’s correlation analysis with reference to the distribution of evaluated variables.
Malodour was related to poor QoL, assessed by DLQI (R2 = 0.17, F = 2.63, p = 0.064 [37];
β = 0.44 ± 0.11, R2 = 0.23, p < 0.001 [33]), the Skindex-19 (R2 = 0.39, F = 8.11, p < 0.001) [37],
the Skindex-29 [38] and the EQ-5D [39]. Moreover, it was observed that NRS for malodour
had an impact on sex life (β = 0.13, p = 0.035) [25] and it was a risk factor for sexual
dysfunction in females (β = 0.07, p < 0.05) but not in men [24].
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Alavi et al.
Canada 2017 [37] NRS 5.02 ± 3.06
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(Pearson χ2 = 5.66,
df = 1, p = 0.017).Skindex-19 65.33 ± 17.18 R2 = 0.39, F = 8.11,p < 0.001 a **
Cuenca-Barrales
et al. Spain. 2019
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Skindex-29 symptoms NS r = 0.733, p < 0.05 ˆ
Skindex-29 emotional NS r = 0.725, p < 0.05 ˆ
Skindex-29 functioning NS r = 0.719, p < 0.05 ˆ
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suppuration




NRS NS EQ-5D NS β= −0.023,p < 0.05 ** NS
BMI, body mass index; DLQI, Dermatology Life Quality Index; EQ-5D, EuroQoL-5D; FSFI-6, six-item Female Sexual Function Index; HS,
hidradenitis suppurativa; HODS, Hidradenitis Suppurativa Odor and Drainage Scale; HS-QoL, Hidradenitis Suppurativa quality-of-life
measure; IIEF-5, five-item International Index of Erectile Function; NRS, Numeric Rating Scale; NS, not specified; QoL, quality of life.
a Correlation are done between malodour severity and QoL assessment tools. * Simple linear regression analysis; ** Multivariate linear
regression analysis; # Multivariate logistic regression analysis; ˆ Pearson correlation.





Assessment Tool Score Assessment Tool Score
Cuenca-Barrales et al.
Spain. 2019 [25] NRS 6.48 ± 3.18 NRS for HS impact on sex life
7.24 ± 2.77 in women





Women: 6.39 ± 3.21 Prevalence of sexual
dysfunction
FSFI-6 ≤ 19 51% (156) β = NS, p = 0.29 **




Skindex-29 NS r = 0.614, p < 0.05 ˆ
Skindex-29 symptoms NS r = 0.619, p < 0.05 ˆ
Skindex-29 emotional NS r = 0.616, p < 0.05 ˆ
Skindex-29 functioning NS r = 0.605, p < 0.05 ˆ
HS-QoL overall NS r = 0.745, p < 0.05 ˆ
FSFI-6, six-item Female Sexual Function Index; HODS, Hidradenitis Suppurativa Odor and Drainage Scale; HS, hidradenitis suppurativa;
HS-QoL, Hidradenitis Suppurativa quality-of-life measure; IIEF-5, five-item International Index of Erectile Function. ˆ Pearson correlation;
** Multivariate linear regression analysis.
4. Discussion
The results of this systematic review and meta-analysis presents the clinical situation
of patients with HS regarding signs and symptoms and summarizes the current evidence
regarding their correlation with QoL impairment, both general and specific. The importance
of the research on this topic is notable and increasing, as the majority of the studies are
published from 2016 onwards.
As previously described, HS has a great impact on QoL [41], even more than other
dermatosis, such as psoriasis or atopic dermatitis [42]. Although most tools used to
assess QoL were validated questionnaires, they differed between studies. The tool most
Int. J. Environ. Res. Public Health 2021, 18, 6709 13 of 17
frequently used to evaluate QoL was the DLQ, showing moderate to large impacts on
patients’ lives [26–28,30,32,33,35,36]. The scores employed to assess signs and symptom
severity were subjective and varied between studies, with the NRS being the most used
tool for symptoms [24,32,33]. Furthermore, it is noteworthy that clinicians from North
America and Asia are less likely to measure HS symptoms, which may reflect regional
differences in clinical assessment or research trends [43].
Pain is the symptom with the strongest correlation with QoL impairment [7,44,45].
Mean pain reported was almost four out of 10, which qualifies as mild-to-moderate pain
considering established cut-offs [46]. These values are like chronic posttraumatic headaches
and worse than vasculitis, blistering disorders, vulvar lichen sclerosis and leg ulcers [19,47].
HS pain is both nociceptive and neuropathic. Nociceptive pain may be the result of acute
inflammation while neuropathic HS pain could be due to chronic inflammation causing
peripheral neuroplastic changes and central sensitization. Addressing HS pain is critical
to improve HS-related QoL and reduce morbidity from opioid and other substance use.
Unfortunately, current HS therapies often provide inadequate pain relief, and studies of HS
pain-directed therapies are sparse. Non-steroidal anti-inflammatory drugs, intralesional
corticosteroids or neuromodulator medications could be effective treatment for pain [44].
Moreover, incorporation of psychological therapies may represent an important opportu-
nity for reducing chronic HS pain [43]. Pain intensity correlated with impairment in QoL
in all the studies included [24–36]. This is in part explained by the physical limitations
caused by the painful lesions. Moreover, pain is associated with poor mental health. Rates
of depression and anxiety are higher in HS patients than in healthy individuals [48–50].
Pro-inflammatory cytokines, including TNF- α, IL-1β and IL-10, are elevated in the lesional
skin of HS patients [49,51]. TNF-α and IL-1β are also increased in major depressive, anxiety
and other psychiatric disorders [52]. Therefore, high levels of these cytokines in HS [49,53]
could explain the relationship between HS and poor mental health. HS also has an impact
on sleep quality, even worse than other systemic conditions, such as lupus erythematosus,
chronic obstructive pulmonary disease or Hodgkin’s lymphoma [54,55]. Sleep disorders
also contribute to decreased QoL [56] and HS pain impact on sleep quality [29]. Sexual
health is likewise an important aspect of patients’ QoL [57] and pain is also a risk factor for
sexual distress and sexual dysfunction [24,25]. Sexual distress reveals the suffering of the
subject while sexual dysfunction might mean a poor sexual experience for both members
of the relationship [25]. The impact of pain in sexual health may be linked to the nature of
the sexual act and psychological factors that may be associated with disease activity [57].
Pruritus is the second symptom with the strongest correlation with poorer
QoL [24,25,29,32–34,39,40]. It might be underreported because patients do not sponta-
neously refer to this symptom unless they are specifically asked [32]. The mean pruritus
reported was almost five out 10. Although HS is not considered as a pruritic disease, this
symptom is commonly associated with HS, mainly during the outbreak of lesions [20,58].
Pruritus severity has been related to overall impairment of QoL [32–34,39], sleep distur-
bances [29,40] and depression [34] but it has not been linked to poor sexual health [24,25].
In agreement with our results, pruritus has been previously described as a potential risk
factor for sleep impairment in other dermatosis [59,60]. The absence of impact on sexual
health might be due to pruritus being less bothersome than pain or it could even decrease
during sexual intercourse. Skin irritation caused by suppuration might be the cause of
pruritus in patients with HS [33]. The increased number of mast cells and inflammatory
cell infiltration in HS lesions might also explain the pruritus in HS [7,32]. The reduction
of suppuration through antibiotics, anti-inflammatories, or surgical procedures, as well
as topical measures to control skin irritation like emollients or corticosteroids, should be
considered in patients with the relevant pruritus and suppuration [33].
Scarce studies have evaluated the impact of malodour and suppuration on
QoL [24,25,33,37–39]. Compared to pain and pruritus, malodour and suppuration can
potentially be perceived by other people and might also contribute to worsen patients QoL
and stigmatization. In fact, malodour can be underestimated by the patients as they get
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used to it, but their partners usually show a more expressive response when they inquire
about this problem. This can potentially cause social, work and personal problems, and
favours stigma and isolation behaviours [33,61], contributing to decreased QoL. Studies
have also shown that malodour and suppuration severity were associated with poorer
sexual QoL only in women, not in men [24]. Although previous investigations indicated
higher sexual distress in women than in men with HS, the impact of different symptoms
between both sexes might be explained by an early onset of HS in women, or even by
cultural aspects and differences in emotional and neuroendocrine response to disfigure-
ment [62]. As previously stated, suppuration is linked to advanced chronic lesions and
bacterial biofilms [63,64]. Intensity of suppuration, Hurley stage, longer disease duration
and high number of regions affected are risk factors for malodour [33]. Structural damage,
as in the presence of scars, may make personal hygiene difficult and favour bacterial
overgrowth thereby increasing molodour and suppuration scores. Body mass index is
associated with malodour probably due to the presence of prominent skin folds and exces-
sive sweating. Control of malodour and suppuration should be a priority in patients with
HS to improve their QoL. Weight loss is advisable in all overweight and obese patients.
Anti-inflammatories, antibiotics or a combination of both should be given in patients with
poor disease control, and antiseptic washes or surgical procedures to remove scarring
tissue could be used in patients with good disease control and structural damage [33].
This systematic review is subject to some limitations. All the designs were cross-
sectional, which limits the inference of causality. Although most of the questionnaires
and tools used are validated, there is heterogeneity between the different studies. There
are also differences in the severity of the patients depending on the source of the patients
(outpatient clinic vs. general surveys). Moreover, some the assessment of these symptoms
is subjective, which may also increase the variability.
Further studies should include validating questionnaires to assess QoL and symptoms
severity. DLQI might be a good option to evaluate overall QoL. NRS for pain, pruritus,
malodour and suppuration should also be included. Outcomes should be reported, both
cut-off (nominal) and average (continuous) data of these questionnaires, in future studies.
5. Conclusions
In conclusion, we have summarized, categorized and analyzed the scientific evidence
regarding signs and symptoms in HS patients and their impairment in QoL. Pain might
be the symptom most related with impairment in QoL due to its high frequency and
subjective component. Malodour is the least studied symptom and could have a major
effect on interpersonal relationships. Assessment of these symptoms should be thorough
and included during routine evaluation of HS patients. It would be important to define
cut-off values of symptom severity to motivate therapeutic modifications. Coordinated
and consistent medical and psychological support are of great importance to increase
patients’ health.
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